UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

(Mark One)

þ		QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

o		TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 1-13252

 

McKESSON CORPORATION

(Exact name of registrant as specified in its charter)

Delaware		94-3207296
(State or other jurisdiction of incorporation or		(I.R.S. Employer Identification No.)
organization)
One Post Street, San Francisco, California		94104
(Address of principal executive offices)		(Zip Code)

     Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o

     Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes þ No o

     Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer þ		Accelerated filer o		Non-accelerated filer o		Smaller reporting company o
		(Do not check if a smaller reporting company)

     Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No þ

     Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Class		Outstanding as of December 31, 2010
Common stock, $0.01 par value		254,260,037 shares

 

 

McKESSON CORPORATION

TABLE OF CONTENTS

Item		Page
PART I. FINANCIAL INFORMATION
1. Condensed Consolidated Financial Statements
Condensed Consolidated Statements of Operations Quarters and Nine Months ended December 31, 2010 and 2009			3
Condensed Consolidated Balance Sheets December 31, 2010 and March 31, 2010			4
Condensed Consolidated Statements of Cash Flows Nine Months ended December 31, 2010 and 2009			5
Financial Notes			6
2. Management’s Discussion and Analysis of Financial Condition and Results of Operations			22
3. Quantitative and Qualitative Disclosures About Market Risk			35
4. Controls and Procedures			35
PART II. OTHER INFORMATION
1. Legal Proceedings			35
1A. Risk Factors			35
2. Unregistered Sales of Equity Securities and Use of Proceeds			35
3. Defaults Upon Senior Securities			35
4. Reserved			35
5. Other Information			35
6. Exhibits			36
Signatures			37
EX-10.1
EX-10.2
EX-31.1
EX-31.2
EX-32
EX-101 INSTANCE DOCUMENT
EX-101 SCHEMA DOCUMENT
EX-101 CALCULATION LINKBASE DOCUMENT
EX-101 LABELS LINKBASE DOCUMENT
EX-101 PRESENTATION LINKBASE DOCUMENT
EX-101 DEFINITION LINKBASE DOCUMENT

McKESSON CORPORATION

PART I. FINANCIAL INFORMATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In millions, except per share amounts)
(Unaudited)

		Quarter Ended								Nine Months Ended
		December 31,								December 31,
		2010				2009				2010				2009
Revenues		$	28,247			$	28,272			$	83,231			$	82,059
Cost of Sales			26,786				26,817				79,012				77,966
Gross Profit			1,461				1,455				4,219				4,093
Operating Expenses			965				946				2,808				2,678
Litigation Charge (Credit)			189				—				213				(20	)
Total Operating Expenses			1,154				946				3,021				2,658
Operating Income			307				509				1,198				1,435
Other Income, Net			7				25				19				39
Interest Expense			(53	)			(47	)			(140	)			(142	)
Income from Continuing Operations Before Income Taxes			261				487				1,077				1,332
Income Tax Expense			(106	)			(161	)			(369	)			(417	)
Income from Continuing Operations			155				326				708				915
Discontinued Operation – gain on sale, net of tax			—				—				72				—
Net Income		$	155			$	326			$	780			$	915
Earnings Per Common Share
Diluted
Continuing operations		$	0.60			$	1.19			$	2.69			$	3.36
Discontinued operation – gain on sale			—				—				0.27				—
Total		$	0.60			$	1.19			$	2.96			$	3.36
Basic
Continuing operations		$	0.61			$	1.21			$	2.73			$	3.41
Discontinued operation – gain on sale			—				—				0.28				—
Total		$	0.61			$	1.21			$	3.01			$	3.41
Dividends Declared Per Common Share		$	0.18			$	0.12			$	0.54			$	0.36
Weighted Average Common Shares
Diluted			258				274				264				272
Basic			254				269				259				269

See Financial Notes

McKESSON CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS
(In millions, except per share amounts)
(Unaudited)

		December 31,						March 31,
		2010						2010
ASSETS
Current Assets
Cash and cash equivalents			$	3,213				$	3,731
Receivables, net				8,647					8,075
Inventories, net				9,547					9,441
Prepaid expenses and other				286					257
Total				21,693					21,504
Property, Plant and Equipment, Net				934					851
Capitalized Software Held for Sale, Net				153					234
Goodwill				4,321					3,568
Intangible Assets, Net				1,596					551
Other Assets				1,699					1,481
Total Assets			$	30,396				$	28,189
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities
Drafts and accounts payable			$	13,581				$	13,255
Deferred revenue				1,357					1,218
Deferred tax liabilities				1,100					977
Current portion of long-term debt				1,757					3
Other accrued liabilities				1,890					1,559
Total				19,685					17,012
Long-Term Debt				2,305					2,293
Other Noncurrent Liabilities				1,326					1,352
Other Commitments and Contingent Liabilities (Note 13)
Stockholders’ Equity
Preferred stock, $0.01 par value, 100 shares authorized, no shares issued or outstanding				—					—
Common stock, $0.01 par value Shares authorized: December 31, 2010 and March 31, 2010 – 800 Shares issued: December 31, 2010 – 365 and March 31, 2010 – 359				4					4
Additional Paid-in Capital				5,153					4,756
Retained Earnings				7,876					7,236
Accumulated Other Comprehensive Income				51					6
Other				2					(12	)
Treasury Shares, at Cost, December 31, 2010 – 111 and March 31, 2010 – 88				(6,006	)				(4,458	)
Total Stockholders’ Equity				7,080					7,532
Total Liabilities and Stockholders’ Equity			$	30,396				$	28,189

See Financial Notes

McKESSON CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In millions)
(Unaudited)

		Nine Months Ended December 31,
		2010				2009
Operating Activities
Net income		$	780			$	915
Discontinued operation – gain on sale, net of tax			(72	)			—
Adjustments to reconcile to net cash provided by operating activities:
Depreciation and amortization			352				350
Asset impairment charge – capitalized software held for sale			72				—
Share-based compensation expense			99				83
Other non-cash items			58				66
Changes in operating assets and liabilities, net of effect of acquisitions:
Receivables			(198	)			(415	)
Inventories			22				(205	)
Drafts and accounts payable			52				1,131
Deferred revenue			82				57
Litigation charge (credit)			213				(20	)
Deferred tax expense on litigation credit			—				116
Litigation settlement payments			(26	)			(350	)
Other			(96	)			(3	)
Net cash provided by operating activities			1,338				1,725
Investing Activities
Property acquisitions			(157	)			(137	)
Capitalized software expenditures			(111	)			(134	)
Acquisitions of businesses, less cash and cash equivalents acquired			(292	)			(18	)
Proceeds from sale of business			109				—
Other			(15	)			86
Net cash used in investing activities			(466	)			(203	)
Financing Activities
Common stock share repurchases, including shares surrendered for tax withholding			(1,548	)			(322	)
Common stock issuances			238				159
Common stock transactions – other			61				26
Dividends paid			(126	)			(98	)
Other			(21	)			(2	)
Net cash used in financing activities			(1,396	)			(237	)
Effect of exchange rate changes on cash and cash equivalents			6				34
Net increase (decrease) in cash and cash equivalents			(518	)			1,319
Cash and cash equivalents at beginning of period			3,731				2,109
Cash and cash equivalents at end of period		$	3,213			$	3,428
Non-cash item:
Fair value of acquisition debt assumed		$	(1,910	)		$	—

See Financial Notes

McKESSON CORPORATION

FINANCIAL NOTES
(UNAUDITED)

1. Significant Accounting Policies

     Basis of Presentation: The condensed consolidated financial statements of McKesson Corporation (“McKesson,” the “Company,” or “we” and other similar pronouns) include the financial statements of all wholly-owned subsidiaries and majority-owned or controlled companies. Intercompany transactions and balances have been eliminated. The condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) and, therefore, do not include all information and footnote disclosures normally included in the annual consolidated financial statements.

     To prepare the financial statements in conformity with GAAP, management must make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of these financial statements and income and expenses during the reporting period. Actual amounts may differ from these estimated amounts. In our opinion, these unaudited condensed consolidated financial statements include all adjustments necessary for a fair presentation of the Company’s financial position as of December 31, 2010, the results of operations for the quarters and nine months ended December 31, 2010 and 2009 and cash flows for the nine months ended December 31, 2010 and 2009.

     The results of operations for the quarter and nine months ended December 31, 2010 are not necessarily indicative of the results that may be expected for the entire year. These interim financial statements should be read in conjunction with the annual audited financial statements, accounting policies and financial notes included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2010 previously filed with the SEC on May 4, 2010 (“2010 Annual Report”). Certain prior period amounts have been reclassified to conform to the current period presentation.

     The Company’s fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year shall mean the Company’s fiscal year.

     Recently Adopted Accounting Pronouncements

     Accounting for Transfers of Financial Assets: On April 1, 2010, we adopted amended accounting guidance for transfers of financial assets, including securitization transactions, in which entities have continued exposure to risks related to transferred financial assets. This amendment changed the requirements for derecognizing financial assets and expanded the disclosure requirements for such transactions. As a result of the amended accounting guidance, from April 1, 2010 forward, accounts receivable transactions under our accounts receivable securitization facility are accounted for as secured borrowings rather than asset sales. Refer to Financial Note 9, “Debt and Financing Activities,” for additional information.

     Consolidations: On April 1, 2010, we adopted amended accounting guidance for consolidation of Variable Interest Entities (“VIEs”). The new guidance eliminates the quantitative approach previously required for determining the primary beneficiary of a VIE and requires ongoing qualitative reassessments of whether an enterprise is the primary beneficiary, including ongoing assessments of control over such entities. The adoption of this amended guidance did not have a material effect on our condensed consolidated financial statements.

     Financing Receivables: On October 1, 2010, we adopted amended accounting guidance which expands disclosures regarding the credit quality of an entity’s receivables portfolio and its related allowance for credit losses. The adoption of the amended guidance did not have a material effect on our condensed consolidated financial statements. Additional disclosure requirements regarding activity during a reporting period will be adopted in the fourth quarter of 2011 and the adoption of these disclosure requirements is not expected to have a material effect on our condensed consolidated financial statements.

McKESSON CORPORATION

FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

     Newly Issued Accounting Pronouncements

     In October 2009, the Financial Accounting Standards Board (“FASB”) issued amended accounting guidance for multiple-deliverable revenue arrangements. The amended guidance affects the determination of when individual deliverables included in a multiple-element arrangement may be treated as separate units of accounting. In addition, the amended guidance modifies the manner in which the transaction consideration is allocated across separately identified deliverables, eliminates the use of the residual value method of allocating arrangement consideration and requires expanded disclosure. The amended guidance will become effective for us for multiple-element arrangements entered into or materially modified on or after April 1, 2011. We are currently evaluating the effect of the amended guidance on our condensed consolidated financial statements.

     In October 2009, the FASB issued amended accounting guidance for certain revenue arrangements that include software elements. The guidance amends pre-existing software revenue recognition guidance by removing from its scope tangible products that contain both software and non-software components that function together to deliver the product’s functionality. The amended guidance will become effective for us for revenue arrangements entered into or materially modified on or after April 1, 2011. We are currently evaluating the effect of the amended guidance on our condensed consolidated financial statements.

     In April 2010, the FASB issued amended accounting guidance for vendors who apply the milestone method of revenue recognition to research and development arrangements. The amended guidance applies to arrangements with payments that are contingent upon achieving substantively uncertain future events or circumstances. The amended guidance is effective on a prospective basis for us for milestones achieved on or after April 1, 2011. We are currently evaluating the effect of the amended guidance on our condensed consolidated financial statements.

2. Business Combinations

     On December 30, 2010, we acquired all of the outstanding shares of US Oncology Holdings, Inc. (“US Oncology”) of The Woodlands, Texas for approximately $2.1 billion, consisting of cash consideration of $0.2 billion, net of cash acquired, and the assumption of liabilities with a fair value of $1.9 billion. As an integrated oncology company, US Oncology is affiliated with community-based oncologists, and works with patients, hospitals, payors and the medical industry across all phases of the cancer research and delivery continuum. The acquisition of US Oncology expands our existing specialty pharmaceutical distribution business and adds practice management services for oncologists. The cash paid at acquisition was funded from cash on hand. Refer to Financial Note 9, “Debt and Financing Activities,” for additional information on the assumption and funding of acquired debt.

     The following table summarizes the preliminary fair values of the assets acquired and liabilities assumed as of the acquisition date, which are included in our condensed consolidated balance sheet at December 31, 2010. Due to the timing of the acquisition, all amounts are subject to change within the measurement period as our fair value assessments are finalized:

(In millions)
Current assets		$	546
Goodwill			774
Intangible assets			1,099
Other long-term assets			396
Current liabilities			(535	)
Current portion of long-term debt			(1,751	)
Other long-term liabilities			(270	)
Other stockholders’ equity			(15	)
Net assets acquired, less cash and cash equivalents		$	244

McKESSON CORPORATION

FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

     Approximately $774 million of the purchase price allocation was assigned to goodwill, which primarily reflects the expected future benefits to be realized upon integrating the business. Included in the purchase price allocation are acquired identifiable intangibles of $1.1 billion primarily representing service agreements and a trade name, the fair value of which was determined by using primarily Level 3 inputs, which are based on unobservable inputs and reflect our own assumptions. The estimated weighted average lives of the service agreements and trade name are 20 years. Financial results for US Oncology were not included in the results of operations for the third quarter and nine months ended December 31, 2010 as they were not material. These results will be included within our Distribution Solutions segment beginning in the fourth quarter of 2011. We incurred $34 million of acquisition-related expenses in the third quarter of 2011 as follows: $24 million recorded in operating expenses in Distribution Solutions segment and $10 million of bridge loan fees recorded in interest expense.

     During the last two years, we also completed a number of other smaller acquisitions within both of our operating segments. Financial results for our business acquisitions have been included in our consolidated financial statements since their respective acquisition dates. Purchase prices for our business acquisitions have been allocated based on estimated fair values at the date of acquisition. Goodwill recognized for our business acquisitions is generally not expected to be deductible for tax purposes. Pro forma results of operations for our business acquisitions have not been presented because the effects were not material to the consolidated financial statements on either an individual or an aggregate basis.

3. Asset Impairment Charge – Capitalized Software Held for Sale

     Our capitalized software held for sale is amortized over three years. At each balance sheet date, or earlier if an indicator of an impairment exists, we evaluate the recoverability of unamortized capitalized software costs based on estimated future undiscounted revenues net of estimated related costs over the remaining amortization period. At the end of the second quarter of 2010, our Horizon Enterprise Revenue Management ^TM (“HzERM”) software product became generally available. In October 2010, we decreased our estimated revenues over the next 24 months for our HzERM software product and as a result, concluded that the estimated future revenues, net of estimated related costs, were insufficient to recover its carrying value. Accordingly, we recorded a $72 million non-cash impairment charge at September 30, 2010 within our Technology Solutions segment’s cost of sales to reduce the carrying value of the software product to its net realizable value.

4. Discontinued Operation

     In July 2010, our Technology Solutions segment sold its wholly-owned subsidiary, McKesson Asia Pacific Pty Limited (“MAP”), a provider of phone and web-based healthcare services in Australia and New Zealand, for net sales proceeds of $109 million. The divestiture generated a pre-tax and after-tax gain of $95 million and $72 million. As a result of the sale we were able to utilize capital loss carry-forwards for which we previously recorded a valuation allowance of $15 million. The release of the valuation allowance is included as a tax benefit in our after-tax gain on the divestiture. The after-tax gain on disposition was recorded as a discontinued operation in our condensed statement of operations in the second quarter of 2011. Should we incur a capital gain within our continuing operations during the remainder of 2011, some portion or all of the $15 million valuation allowance reversal could be reclassified to continuing operations. The historical financial operating results and net assets of MAP were not material to our condensed consolidated financial statements for all periods presented.

5. Share-Based Compensation

     We provide share-based compensation for our employees, officers and non-employee directors, including stock options, an employee stock purchase plan, restricted stock units (“RSUs”) and performance-based restricted stock units (“PeRSUs”) (collectively, “share-based awards”).

     Compensation expense for stock options is recognized on a straight-line basis over the requisite service period and is based on the grant-date fair value for the portion of the awards that is ultimately expected to vest.

McKESSON CORPORATION

FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

     RSUs, which entitle the holder to receive, at the end of a vesting term, a specified number of shares of the Company’s common stock are accounted for at fair value at the date of grant. The fair value of RSUs under our stock plans is determined by the product of the number of shares that are expected to vest and the grant date market price of the Company’s common stock. These awards generally vest in four years. We recognize expense for RSUs with a single vest date on a straight-line basis over the requisite service period. We have elected to expense the grant date fair value of RSUs with only graded vesting and service conditions on a straight-line basis over the requisite service period.

     PeRSUs are RSUs for which the number of RSUs awarded may be conditional upon the attainment of one or more performance objectives over a specified period. PeRSUs are accounted for as variable awards generally for one year until the performance goals are reached and the grant date is established. The fair value of PeRSUs is determined by the product of the number of shares eligible to be awarded and expected to vest, and the market price of the Company’s common stock, commencing at the inception of the requisite service period. During the performance period, the PeRSUs are re-valued using the market price and the performance modifier at the end of a reporting period. At the end of the performance period, if the goals are attained, the awards are granted and classified as RSUs and accounted for on that basis. For PeRSUs granted prior to 2009 with multiple vest dates, we recognize the fair value expense of these awards on a graded vesting basis over the requisite service period of four years. PeRSUs granted during 2009 and after and the related RSUs (when they are granted) have a single vest date for which we recognize expense on a straight-line basis over the four year service period.

     Compensation expense for the share-based awards is recognized for the portion of the awards that is ultimately expected to vest. We develop an estimate of the number of share-based awards, which will ultimately vest primarily based on historical experience. The estimated forfeiture rate established upon grant is re-assessed throughout the requisite service period. As required, the forfeiture estimates are adjusted to reflect actual forfeitures when an award vests. The actual forfeitures in future reporting periods could be higher or lower than current estimates.

     Compensation expense recognized is classified in the condensed consolidated statements of operations or capitalized on the condensed consolidated balance sheets in the same manner as cash compensation paid to our employees. There was no material share-based compensation expense capitalized as part of the cost of an asset for the quarters and nine months ended December 31, 2010 and 2009.

     The components of share-based compensation expense and the related tax benefit for the quarters and nine months ended December 31, 2010 and 2009 are shown in the following table:

		Quarter Ended								Nine Months Ended
		December 31,								December 31,
(In millions)		2010				2009				2010				2009
RSUs (1)		$	18			$	11			$	61			$	37
PeRSUs (2)			7				12				15				25
Stock options			6				5				17				14
Employee stock purchase plan			2				2				6				7
Share-based compensation expense			33				30				99				83
Tax benefit for share-based compensation expense (3)			(12	)			(11	)			(35	)			(30	)
Share-based compensation expense, net of tax		$	21			$	19			$	64			$	53

(1)		This expense was primarily the result of PeRSUs awarded in prior years, which converted to RSUs due to the attainment of goals during the applicable years’ performance period.
(2)		Represents estimated compensation expense for PeRSUs that are conditional upon attaining performance objectives during the current year’s performance period.
(3)		Income tax expense is computed using the tax rates of applicable tax jurisdictions. Additionally, a portion of pre-tax compensation expense is not tax-deductible.

McKESSON CORPORATION

FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

     Share-based compensation expense is affected by our stock price, the number and type of annual share-based awards as well as assumptions regarding a number of complex and subjective variables and the related tax impact. These variables include, but are not limited to, the volatility of our stock price, employee stock option exercise behavior and the attainment of performance goals. As a result, the actual future share-based compensation expense may differ from historical amounts.

6. Income Taxes

     As of December 31, 2010, we had $674 million of unrecognized tax benefits, of which $438 million would reduce income tax expense and the effective tax rate if recognized. During the next twelve months, it is reasonably possible that audit resolutions and the expiration of statutes of limitations could potentially reduce our unrecognized tax benefits by up to $2 million. However, this amount may change because we continue to have ongoing negotiations with various taxing authorities throughout the year.

     We have received assessments of $169 million, including tax and interest, from the Canada Revenue Agency and certain provinces related to a transfer pricing issue for 2003 through 2007. We have appealed the assessment for 2003 to the Canadian Tax Court and have filed a notice of objection for 2004 through 2007. Payments of most of the assessments have been made to stop the accrual of interest. We believe that we have adequately provided for any potential adverse results.

     In nearly all jurisdictions, the tax years prior to 2003 are no longer subject to examination. We believe that we have made adequate provision for all remaining income tax uncertainties.

     We continue to report interest and penalties on tax deficiencies as income tax expense. At December 31, 2010, before any tax benefits, our accrued interest on unrecognized tax benefits amounted to $128 million. We recognized an income tax expense of $4 million and $13 million, before any tax effect, related to interest in our condensed consolidated statements of operations during the third quarter and nine months ended December 31, 2010. We have no material amounts accrued for penalties.

McKESSON CORPORATION

FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

7. Earnings Per Common Share

     Basic earnings per common share are computed by dividing net income by the weighted average number of common shares outstanding during the reporting period. Diluted earnings per common share are computed similar to basic earnings per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock.

     The computations for basic and diluted earnings per common share are as follows:

		Quarter Ended								Nine Months Ended
		December 31,								December 31,
(In millions, except per share amounts)		2010				2009				2010				2009
Income from continuing operations		$	155			$	326			$	708			$	915
Discontinued operation – gain on sale, net of tax			—				—				72				—
Net income		$	155			$	326			$	780			$	915
Weighted average common shares outstanding:
Basic			254				269				259				269
Effect of dilutive securities:
Options to purchase common stock			2				3				3				3
Restricted stock/ restricted stock units			2				2				2				1
Diluted (1)			258				274				264				272
Earnings Per Common Share: (1)
Diluted
Continuing operations		$	0.60			$	1.19			$	2.69			$	3.36
Discontinued operation – gain on sale			—				—				0.27				—
Total		$	0.60			$	1.19			$	2.96			$	3.36
Basic
Continuing operations		$	0.61			$	1.21			$	2.73			$	3.41
Discontinued operation – gain on sale			—				—				0.28				—
Total		$	0.61			$	1.21			$	3.01			$	3.41

(1)		Certain computations may reflect rounding adjustments.

     Potentially dilutive shares include outstanding stock options, RSUs and PeRSUs. Approximately 1 million and 2 million of potentially dilutive shares were excluded from the computations of diluted net earnings per common share for the quarters ended December 31, 2010 and 2009, as they were anti-dilutive. For the nine months ended December 31, 2010 and 2009, the number of potentially dilutive shares excluded was approximately 6 million and 8 million.

McKESSON CORPORATION

FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

8. Goodwill and Intangible Assets, Net

     Changes in the carrying amount of goodwill were as follows:

		Distribution				Technology
(In millions)		Solutions				Solutions				Total
Balance, March 31, 2010		$	1,871			$	1,697			$	3,568
Goodwill acquired, net of purchase price adjustments			783				8				791
Foreign currency translation adjustments and other			(30	)			(8	)			(38	)
Balance, December 31, 2010		$	2,624			$	1,697			$	4,321

     Information regarding intangible assets is as follows:

		December 31,				March 31,
(In millions)		2010				2010
Customer lists		$	934			$	832
Service agreements			723				—
Trademarks and trade names			347				45
Technology			193				190
Other			30				29
Gross intangibles			2,227				1,096
Accumulated amortization			(631	)			(545	)
Intangible assets, net		$	1,596			$	551

     Amortization expense of intangible assets was $28 million and $84 million for the quarter and nine months ended December 31, 2010 and $31 million and $90 million for the quarter and nine months ended December 31, 2009. The weighted average remaining amortization periods for customer lists, service agreements, trademarks and trade names, technology and other intangible assets at December 31, 2010 were: 6 years, 20 years, 19 years, 2 years and 3 years. Estimated annual amortization expense of these assets is as follows: $128 million, $171 million, $154 million, $141 million and $123 million for 2011 through 2015 and $963 million thereafter. All intangible assets were subject to amortization as of December 31, 2010 and March 31, 2010. The amounts assigned to goodwill and intangible assets relating to the acquisition of US Oncology are preliminary and are subject to change based on the final fair value assessment. Refer to Financial Note 2, “Business Combinations,” for additional information.

McKESSON CORPORATION

FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

9. Debt and Financing Activities

     US Oncology Debt Acquired

     Upon our purchase of US Oncology in December 2010, we assumed the outstanding debt of US Oncology Holdings, Inc. and its wholly owned subsidiary US Oncology, Inc. Refer to Financial Note 2, “Business Combinations,” for additional information. Immediately prior to our acquisition, US Oncology Holdings, Inc. called for redemption all of its outstanding Senior Unsecured Floating Rate Toggle Notes (“Floating Rate Notes”) due 2012 and US Oncology, Inc. called for redemption all of its outstanding 9.125% Senior Secured Notes due 2017 (“Secured Notes”) and 10.75% Senior Subordinated Notes due 2014 (“Subordinated Notes”). Redemption will occur during our fourth quarter and as a result all of these notes are included in the current portion of long-term debt in our condensed consolidated balance sheet.

     The fair value of the debt acquired was determined by using primarily Level 3 inputs, which are based on unobservable inputs and reflect our own assumptions. The fair value of the principal amounts of outstanding debt and associated redemption premiums as applicable, are as follows:

(In millions)
Floating Rate Notes, due 2012		$	529
Secured Notes, due 2017			923
Subordinated Notes, due 2014			288
Other			11
Current portion of long-term debt acquired			1,751
Long-term debt acquired			31
Total debt acquired		$	1,782

     We redeemed the Floating Rate Notes, including accrued interest, on January 31, 2011 for $540 million. In the fourth quarter of 2011, we will redeem the Secured Notes and the Subordinated Notes using cash on hand and borrowings under our Senior Bridge Term Loan Facility.

     Senior Bridge Term Loan Facility

     In connection with our execution of an agreement to acquire US Oncology, in November 2010 we entered into a $2.0 billion unsecured Senior Bridge Term Loan Agreement (“Bridge Loan”). In December 2010, we reduced the Bridge Loan commitment to $1.0 billion. On January 31, 2011, we borrowed $1 billion under the Bridge Loan. Borrowings under the Bridge Loan must be repaid in full no later than December 30, 2011 or, in full or in part, upon certain events occurring prior to such time, including specified debt and equity issuances and asset sales. The Bridge Loan bears interest based on the London Interbank Offered Rate plus a margin based on the Company’s credit ratings and the amount of time any borrowings under the Bridge Loan remain outstanding. Amounts repaid under the Bridge Loan cannot be redrawn by the Company. The Bridge Loan contains debt covenants similar to those in our existing revolving credit facility. We anticipate repaying funds obtained from the Bridge Loan and replacing cash resources used to redeem the US Oncology debt with long-term financing.

McKESSON CORPORATION

FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

     Accounts Receivable Securitization Facility

     In May 2010, we renewed our accounts receivable securitization facility (the “Facility”) for an additional one year period under terms substantially similar to those previously in place, and in doing so, we increased our committed balance from $1.1 billion to $1.35 billion. From time-to-time the available amount of the Facility may be less than $1.35 billion based on accounts receivable concentration limits and other eligibility requirements. The renewed Facility will expire in May 2011.

     Through the Facility, McKesson Corporation, the parent company, transfers certain U.S. pharmaceutical trade accounts receivable on a non-recourse basis to a wholly-owned and consolidated subsidiary which then sells these receivables to a special purpose entity (“SPE”), which is a wholly-owned, bankruptcy-remote subsidiary of McKesson Corporation that is consolidated in our financial statements. This SPE then sells undivided interests in the pool of accounts receivable to third-party purchaser groups (the “Purchaser Groups”), which include financial institutions and commercial paper conduits.

     Interests in the pool of accounts receivable that are sold to the Purchaser Groups and accounts receivable retained by the Company are carried at face value which, due to the short-term nature of our accounts receivable and terms of the Facility, approximates fair value. McKesson receives cash in the amount of the face value for the undivided interests sold. No gain or loss is recorded upon the utilization of the facility as fee charges from the Purchaser Groups are based upon a floating yield rate and the period the undivided interests remain outstanding.

     The Facility contains requirements relating to the performance of the accounts receivable and covenants relating to the SPE and the Company. If we do not comply with these covenants, our ability to use the Facility may be suspended and repayment of any outstanding balances under the Facility may be required. At December 31, 2010 and March 31, 2010, we were in compliance with all covenants. Should we default under the Facility, the Purchaser Groups are entitled to receive only collections on the accounts receivable owned by the SPE.

     Prior to 2011, transactions in the Facility were accounted for as sales because we met the requirements of the existing accounting guidance, including relinquishing control of the accounts receivable. Accordingly, accounts receivable sold would have been excluded from accounts receivable, net in the accompanying March 31, 2010 condensed consolidated balance sheet had any balances been outstanding in the Facility at that date. On April 1, 2010, the Company adopted the new accounting standard for transfers of financial assets. Transactions under the Facility no longer meet the requirements for sale as defined in the new accounting standard primarily because the Company’s retained interest in the pool of accounts receivable is subordinated to the Purchaser Groups to the extent there is any outstanding balance in the Facility. Consequently, the related accounts receivable would continue to be recognized on the Company’s condensed consolidated balance sheets and proceeds from the Purchaser Groups would be shown as secured borrowings. Commencing in 2011, fees charged from the Purchaser Groups are recorded in interest expense within the condensed consolidated statements of operations. Prior to 2011, these fees were recorded in Corporate administrative expenses. These fees were not material to our condensed consolidated financial statements. Additionally, any proceeds from these accounts receivable transactions would be reflected in the financing section within the condensed statements of cash flows.

     We continue servicing the accounts receivable sold. No servicing asset is recorded at the time of utilization of the facility because we do not receive any servicing fees from third parties or other income related to servicing the receivable. We do not record any servicing liability at the time of the utilization of the facility as the accounts receivable collection period is relatively short and the costs of servicing the accounts receivable over the servicing period are insignificant. Servicing costs are recognized as incurred over the servicing period.

     At December 31, 2010, there were no securitized accounts receivable balances or secured borrowings outstanding under the Facility. As of March 31, 2010, there were no accounts receivable sold under the Facility. Additionally, there were no sales of interests to the Purchaser Groups in the quarters and nine months ended December 31, 2010 or 2009.

McKESSON CORPORATION

FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

     Revolving Credit Facility

     We have a syndicated $1.3 billion five-year senior unsecured revolving credit facility, which expires in June 2012. Borrowings under this credit facility bear interest based upon either a Prime rate or the London Interbank Offered Rate. There were no borrowings under this facility for the first nine months of 2011 and 2010. As of December 31, 2010 and March 31, 2010, there was no debt balance under this facility; however, there was $40 million in letters of credit issued under this facility which reduces the amount available for borrowing.

10. Pension and Other Postretirement Benefit Plans

     Net periodic expense for the Company’s defined pension and other postretirement benefit plans was $11 million and $29 million for the third quarter and first nine months of 2011 compared to $7 million and $19 million for the comparable prior year periods. Cash contributions to these plans for the first nine months of 2011 were $15 million.

     As previously reported in our 2010 Annual Report, the McKesson Corporation Profit Sharing Investment Plan (“PSIP”) was a member of the settlement class in the Consolidated Securities Litigation Action. On October 9, 2009, the PSIP received approximately $119 million of the Consolidated Securities Litigation Action proceeds. Approximately $42 million of the proceeds were attributable to the allocated shares of McKesson common stock owned by the PSIP participants during the Consolidated Securities Litigation Action class-holding period and were allocated to the respective participants on that basis in the third quarter of 2010. Approximately $77 million of the proceeds were attributable to the unallocated shares (the “Unallocated Proceeds”) of McKesson common stock owned by the PSIP in an employee stock ownership plan (“ESOP”) suspense account. In accordance with the plan terms, the PSIP distributed all of the Unallocated Proceeds to current PSIP participants after the close of the plan year in April 2010. The receipt of the Unallocated Proceeds by the PSIP was reimbursement for the loss in value of the Company’s common stock held by the PSIP in its ESOP suspense account during the Consolidated Securities Litigation Action class holding period and was not a contribution made by the Company to the PSIP or ESOP. Accordingly, there were no accounting consequences to the Company’s financial statements relating to the receipt of the Unallocated Proceeds by the PSIP.

     As a result of the PSIP’s receipt of the $119 million settlement, in 2010 the Company contributed $1 million to the PSIP. Accordingly, PSIP expense for 2010 was nominal. In 2011 the Company resumed its contributions to the PSIP.

     PSIP expense for the quarters and nine months ended December 31, 2010 and 2009 was as follows:

		Quarter Ended								Nine Months Ended
		December 31,								December 31,
(In millions)		2010				2009				2010				2009
Distribution Solutions		$	5			$	—			$	17			$	—
Technology Solutions			7				—				24				1
Corporate			1				—				3				—
PSIP expense		$	13			$	—			$	44			$	1
Cost of sales (1)		$	3			$	—			$	10			$	—
Operating expenses			10				—				34				1
PSIP expense		$	13			$	—			$	44			$	1

(1)		Amounts recorded to cost of sales pertain solely to our Technology Solutions segment.

McKESSON CORPORATION

FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

11. Financial Instruments

     At December 31, 2010 and March 31, 2010, the carrying amounts of cash and cash equivalents, restricted cash, marketable securities, receivables, drafts and accounts payable and other current liabilities approximated their estimated fair values because of the short maturity of these financial instruments. All highly liquid debt instruments purchased with original maturity of three months or less at the date of acquisition are included in cash and cash equivalents. Included in cash and cash equivalents at December 31, 2010 and March 31, 2010 were money market fund investments of $1.7 billion and $2.3 billion, which are reported at fair value. The fair value of these investments was determined by using quoted prices for identical investments in active markets which are considered to be Level 1 inputs under the fair value measurements and disclosure guidance. The carrying value of all other cash equivalents approximates fair value due to their relatively short-term nature.

     The carrying amounts and estimated fair values of our long-term debt and other financing were $4.1 billion and $4.3 billion at December 31, 2010, and $2.3 billion and $2.5 billion at March 31, 2010. The estimated fair value of our long-term debt and other financing was determined using quoted market prices and other inputs that were derived from available market information, which are considered to be Level 2 inputs under the fair value measurements and disclosure guidance, and may not be representative of actual values that could have been realized or that will be realized in the future.

12. Financial Guarantees and Warranties

     Financial Guarantees

     We have agreements with certain of our Canadian customers’ financial institutions under which we have guaranteed the repurchase of our customers’ inventory or our customers’ debt in the event that our customers are unable to meet their obligations to those financial institutions. For our inventory repurchase agreements, among other conditions, inventories must be in resalable condition and any repurchases would be at a discount. Inventory repurchase agreements mostly range from one to two years. Our customer debt guarantees are primarily provided to facilitate financing for certain customers and are generally secured by certain assets of the customer. We also have an agreement with one software customer that, under limited circumstances, may require us to secure standby financing. Because the amount of the standby financing is not explicitly stated, the overall amount of this guarantee cannot reasonably be estimated. At December 31, 2010, the maximum amounts of inventory repurchase guarantees and other customer guarantees were $118 million and $34 million, none of which had been accrued.

     In addition, at December 31 2010, our banks and insurance companies have issued $144 million of standby letters of credit and surety bonds, which were issued on our behalf mostly related to our customer contracts and in order to meet the security requirements for statutory licenses and permits, court and fiduciary obligations and our workers’ compensation and automotive liability programs.

     Our software license agreements generally include certain provisions for indemnifying customers against liabilities if our software products infringe a third party’s intellectual property rights. To date, we have not incurred any material costs as a result of such indemnification agreements and have not accrued any liabilities related to such obligations.

     In conjunction with certain transactions, primarily divestitures, we may provide routine indemnification agreements (such as retention of previously existing environmental, tax and employee liabilities) whose terms vary in duration and often are not explicitly defined. Where appropriate, obligations for such indemnifications are recorded as liabilities. Because the amounts of these indemnification obligations often are not explicitly stated, the overall maximum amount of these commitments cannot be reasonably estimated. Other than obligations recorded as liabilities at the time of divestiture, we have historically not made significant payments as a result of these indemnification provisions.

McKESSON CORPORATION

FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

     Warranties

     In the normal course of business, we provide certain warranties and indemnification protection for our products and services. For example, we provide warranties that the pharmaceutical and medical-surgical products we distribute are in compliance with the U.S. Federal Food, Drug, and Cosmetic Act and other applicable laws and regulations. We have received the same warranties from our suppliers, which customarily are the manufacturers of the products. In addition, we have indemnity obligations to our customers for these products, which have also been provided to us from our suppliers, either through express agreement or by operation of law.

     We also provide warranties regarding the performance of software and automation products we sell. Our liability under these warranties is to bring the product into compliance with previously agreed upon specifications. For software products, this may result in additional project costs, which are reflected in our estimates used for the percentage-of-completion method of accounting for software installation services within these contracts and our estimates of recoverability of capitalized software held for sale. In addition, most of our customers who purchase our software and automation products also purchase annual maintenance agreements. Revenues from these maintenance agreements are recognized on a straight-line basis over the contract period and the cost of servicing product warranties is charged to expense when claims become estimable. Accrued warranty costs were not material to the condensed consolidated balance sheets.

13. Other Commitments and Contingent Liabilities

     In addition to commitments and obligations in the ordinary course of business, we are subject to various claims, other pending and potential legal actions for damages, investigations relating to governmental laws and regulations and other matters arising out of the normal conduct of our business. In accordance with accounting guidance on contingencies, we record a provision for a liability when management believes that it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. We believe we have adequate provisions for any such matters. Management reviews these provisions at least quarterly and adjusts these provisions to reflect the impact of negotiations, settlements, rulings, advice of legal counsel and other information and events pertaining to a particular case. Because litigation outcomes are inherently unpredictable, these decisions often involve a series of complex assessments by management about future events that can rely heavily on estimates and assumptions and it is possible that the ultimate cost of these matters could impact our earnings, either negatively or positively, in the quarter of their resolution.

     Based on our experience, we believe that any damage amounts claimed in the specific matters referenced in our 2010 Annual Report, in our Forms 10-Q for the quarters ended June 30, 2010 and September 30, 2010 and those matters discussed below are not meaningful indicators of our potential liability. We believe that we have valid defenses to these legal proceedings and are defending the matters vigorously. Nevertheless, the outcome of any litigation is inherently uncertain. We are currently unable to estimate the remaining possible losses in these unresolved legal proceedings. Should any one or a combination of more than one of these proceedings against us be successful, or should we determine to settle any or a combination of these matters, we may be required to pay substantial sums, become subject to the entry of an injunction, or be forced to change the manner in which we operate our business, which could have a material adverse impact on our financial position or results of operations.

     As more fully described in our previous public reports filed with the SEC, we are involved in numerous legal proceedings. For a discussion of these proceedings, please refer to the Financial Notes entitled “Other Commitments and Contingent Liabilities” included in our 2010 Annual Report on Form 10-K and in our Forms 10-Q for the quarters ended June 30, 2010 and September 30, 2010. Significant developments in previously reported proceedings and in other litigation and claims since the referenced filings are set out below.

McKESSON CORPORATION

FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

     A. Average Wholesale Price Litigation Matters

     As previously reported regarding the coordinated public payor Average Wholesale Price (“AWP”) actions, collectively In re McKesson Governmental Entities Average Wholesale Price Litigation, filed against the Company in the United States District Court for Massachusetts and relating to alleged misstatements and manipulations of a benchmark for drug reimbursement known as AWP, Board of County Commissioners of Douglas County, Kansas et al. v. McKesson Corporation, Civil Action No. 1:08-CV-11349-PBS (“Douglas County, Kansas Action”); San Francisco Health Plan v. McKesson Corporation, Civil Action No. 1:08-CV-10843-PBS (“San Francisco Action"); and State of Connecticut v. McKesson Corporation, Civil Action No. 1:08-CV-10900-PBS (“Connecticut Action”), the court has not yet issued its ruling on class certification in the Douglas County, Kansas and San Francisco Actions. On November 8, 2010, the Court entered a Notice of Dismissal with prejudice in the Connecticut Action pursuant to the previously reported settlement agreement that the Company executed with the State of Connecticut on October 15, 2010. On December 2, 2010, the Company executed a Memorandum of Understanding documenting an agreement in principal with the States of Oklahoma and Montana to settle and release those States’ share of their Medicaid claims in the Douglas County, Kansas case subject to consent from the federal government not to seek any portion of the settlement recovery. In light of the Memorandum of Understanding, on December 7, 2010, the Court vacated the previously reported trial date of January 24, 2011.

     On November 9, 2010, the Company filed a Notice of Removal to the United States District Court, Southern District of Mississippi, in the previously reported action originally filed in Mississippi state court by the State of Mississippi against the Company, State of Mississippi v. McKesson Corporation, et al., Case No. 251-10-862CIV. On January 14, 2011, the parties jointly submitted to the court a proposed order which, if entered, will remand the case back to Mississippi state court. The Company has not yet responded to the complaint in this matter.

     On November 22, 2010, the Company filed a motion to dismiss the previously reported action filed in Kansas state court by the State of Kansas against the Company and First Databank, Inc., State of Kansas ex rel. Steve Six v. McKesson Corporation, et al., Case No. 10CV1491. The hearing on the Company’s motion to dismiss is currently scheduled for February 24, 2011.

     On December 14, 2010, the previously reported qui tam action filed by four law firms in Wisconsin state court, purportedly on behalf of the State of Wisconsin, State of Wisconsin ex rel. Hagens Berman Sobol Shapiro LLP, et al. v. McKesson Corporation, Case No. 10CV3411, was dismissed on motion by the State of Wisconsin.

     On December 22, 2010, the Company filed a motion to dismiss the previously reported action filed in the United States District Court, Northern District of California, by the State of Utah against the Company, State of Utah v. McKesson Corporation, et al., Case No. CV 10-4743-SI. The hearing on the Company’s motion to dismiss is currently scheduled for February 11, 2011.

     On October 12, 2010, an action was filed in Alaska state court by the State of Alaska against the Company and First Databank, Inc., based on essentially the same factual allegations as alleged in In re McKesson Governmental Entities Average Wholesale Price Litigation, asserting claims under state unfair and deceptive trade practices statutes, and for fraud and civil conspiracy, and seeking damages, treble damages, punitive damages, civil penalties, disgorgement of profits, as well as declaratory relief, interest, attorneys’ fees and costs of suit, all in unspecified amounts, State of Alaska v. McKesson Corporation, et al., Case No. 3AN-10-11348-CI. The Company filed a motion to dismiss the complaint on January 10, 2011.

McKESSON CORPORATION

FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

     On November 5, 2010, the Company received a Notice of Proposed Civil Monetary Penalty from the Office of Inspector General (“OIG”) for the Arizona Health Care Cost Containment System Administration purporting to initiate an administrative claim process against the Company based on essentially the same factual allegations as alleged in In re McKesson Governmental Entities Average Wholesale Price Litigation, and seeking civil penalties in the amount of $101 million and an assessment in the amount of $112 million for false claims allegedly presented to the Arizona Medicaid program, Case No. 2010-1218. The Company intends to challenge the imposition of the Proposed Civil Monetary Penalty by the OIG.

     On November 10, 2010, an action was filed in Hawaii state court by the State of Hawaii against the Company and First Databank, Inc., based on essentially the same factual allegations as alleged in In re McKesson Governmental Entities Average Wholesale Price Litigation, asserting claims under the Hawaii False Claims Act, state unfair and deceptive trade practices statutes, fraud, and civil conspiracy, and seeking damages, treble damages, punitive damages, civil penalties, disgorgement of profits, as well as interest, attorneys’ fees and costs of suit, all in unspecified amounts, State of Hawaii v. McKesson Corporation, et al., Civil No. 10-1-2411-11-GWBC. The Company filed a motion to dismiss the complaint on January 14, 2011.

     On December 20, 2010, an action was filed in Louisiana state court by the State of Louisiana against the Company based on essentially the same factual allegations as alleged in In re McKesson Governmental Entities Average Wholesale Price Litigation, asserting claims under state unfair and deceptive trade practices statutes, the Louisiana Medical Assistance Programs Integrity Law, state antitrust statutes, and for fraud, negligent misrepresentation, civil conspiracy, and unjust enrichment, seeking damages, statutory fines, civil penalties, disgorgement of profits, as well as interest, attorneys’ fees and costs of suit, all in unspecified amounts, State of Louisiana v. McKesson Corporation, Case No. C597634 Sec. 23. The Company has not yet responded to the complaint in this matter.

     As previously reported, the Company was informed in June of 2007 that a qui tam action by an unknown relator had been previously filed in the United States District Court for the District of New Jersey, purportedly on behalf of the United States, twelve states (California, Delaware, Florida, Hawaii, Illinois, Louisiana, Massachusetts, Nevada, New Mexico, Tennessee, Texas and Virginia) and the District of Columbia against the Company and seven other defendants. In January 2009, the Company was provided with a courtesy copy of a third amended complaint filed in the qui tam action. Neither the original nor the amended complaint has ever been served on the Company. The third amended complaint alleges multiple claims against the Company under the federal False Claims Act and the various states’ and District of Columbia’s false claims statutes. These and additional claims are also alleged against other parties. The claims arise out of alleged manipulation of AWP by defendants which plaintiffs claim caused them to pay more than they should have in reimbursement for prescription drugs covered by various government programs that base reimbursement payments on AWP. The amended complaint was brought by the relator on behalf of the United States, the twelve states named above, ten additional states (Georgia, Indiana, Michigan, Montana, New Hampshire, New Jersey, New York, Oklahoma, Rhode Island and Wisconsin) and the District of Columbia and seeks damages including treble damages and civil penalties.

     As has also been previously reported regarding the New Jersey qui tam action, the United States and various states have been considering whether to intervene in the suit, but none has done so to date. The Company has at all times cooperated with these investigations, and has engaged in settlement discussions with the purpose of resolving all Medicaid related AWP claims by the states and federal government. The pace and progress of settlement discussions accelerated during and after the third quarter of 2011. Except as previously reported with respect to the States of Connecticut, Oklahoma and Montana, the Company has not reached agreement relating to those claims.

     As previously reported, during the third quarter of 2009, the Company recorded a pre-tax charge of $143 million to establish a reserve for estimated probable losses related to pending and expected claims by public payor entities. As of March 31, 2009 and 2010, the reserve relating to AWP public entity claims was $143 million. The Company recorded an additional pre-tax charge of $24 million for the settlement with the State of Connecticut during the second quarter of 2011. In November 2010, a cash payment of $26 million was made for this settlement. Following the Company’s most recent review of the reserve for estimated probable losses from current and possible future public entity AWP claims, which review included consideration of the pace and progress of the above described settlement discussions during and after the third quarter relating to state and federal Medicaid claims, the Company recorded a pre-tax charge of $189 million within its Distribution Solutions segment’s operating expenses during the third quarter of 2011. As of December 31, 2010, the reserve relating to AWP public entity claims was $330 million and was included in other current liabilities in the condensed consolidated balance sheet. However, in view of the number of outstanding cases and expected future claims, and the uncertainties of the timing and outcome of this type of litigation, it is possible that the ultimate costs of these matters may exceed or be less than the reserve.

     B. Other Litigation and Claims

     As previously reported, on April 7, 2010 an action was filed in the Superior Court of the State of California for the County of Los Angeles against, among others, the Company, its indirect subsidiary, NDCHealth Corporation (“NDC”) and “RelayHealth,” a trade name under which NDC conducts business, Rodriguez et al. vs. Etreby Computer Company et al. , (Civ. No. BC435303) (“Rodriguez”), in which plaintiffs represent a class of California residents whose individual confidential medical information was allegedly illegally released and used by defendants. On May 10, 2010, defendants removed the action to United States District Court for the Central District of California, Rodriguez et al. vs. Etreby Computer Company, et al. (Civil Action No. CV 10-3522-VBF). On December 9, 2010, the parties in this matter executed a settlement agreement which, in consideration of payment by the Company of a non-material sum, resolves the claims of all class members who do not affirmatively opt out of the class. The settlement requires notice to the class in a form acceptable to the trial court and is subject to the court’s preliminary and final approval. On January 12, 2011, the trial court issued an order granting preliminary approval of the settlement, directing notice to the class and setting a June 13, 2011 hearing for final approval of the settlement.

     Prior to its recent acquisition by the Company, US Oncology was informed that the United States Federal Trade Commission (“FTC”) and the Attorney General for the State of Texas had opened investigations to determine whether a transaction in which certain Austin, Texas based oncology physicians became employees of an existing Texas US Oncology affiliated oncology practice group violated relevant state or federal antitrust laws. US Oncology has responded to requests for information from the government agencies and the Company intends to continue to cooperate with the FTC and the Texas Attorney General regarding these investigations.

McKESSON CORPORATION

FINANCIAL NOTES (CONTINUED)
(UNAUDITED)

14. Stockholders’ Equity

     Each share of the Company’s outstanding common stock is permitted one vote on proposals presented to stockholders and is entitled to share equally in any dividends declared by the Company’s Board of Directors (the “Board”).

     Share Repurchase Plans

     In April 2008, the Company’s Board of Directors (the “Board”) approved a plan to repurchase $1.0 billion of the Company’s common stock, of which $531 million remained available as of March 31, 2010.

     April 2010, the Board authorized a plan to repurchase up to an additional $1.0 billion of the Company’s common stock. In May 2010, we entered into a capped accelerated share repurchase (“ASR”) program with a third party financial institution to repurchase $1.0 billion of the Company’s common stock. As a result of the ASR program, we repurchased 12.7 million shares for $1.0 billion during the first quarter of 2011, which was funded with cash on hand. The ASR program was completed on July 26, 2010 and we received 1.9 million additional shares on July 29, 2010. The total number of shares repurchased under the ASR program was 14.6 million shares at an average price per share of $68.66.

     In addition, we repurchased 8.6 million shares for $531 million during the second quarter of 2011 through regular open market transactions at an average price per share of $61.34.

     As a result of these purchases, the April 2008 and April 2010 plans have been completed and no amounts remain authorized for repurchase under these plans.

     In October 2010, the Board authorized a plan to repurchase up to an additional $1.0 billion of the Company’s common stock. No shares were repurchased during the third quarter of 2011.

     Stock repurchases may be made from time-to-time in open market transactions, privately negotiated transactions, through accelerated share repurchase programs, or by any combination of such methods. The timing of any repurchases and the actual number of shares repurchased will depend on a variety of factors, including our stock price, corporate and regulatory requirements, restrictions under our debt obligations and other market and economic conditions.

     Dividend Policy

     In May 2010, the quarterly dividend was raised from $0.12 to $0.18 per common share. The Company anticipates that it will continue to pay quarterly cash dividends in the future. However, the payment and amount of future dividends remain within the discretion of the Board and will depend upon the Company’s future earnings, financial condition, capital requirements and other factors.

     Comprehensive Income

     Comprehensive income is as follows:

		Quarter Ended								Nine Months Ended
		December 31,								December 31,
(In millions)		2010				2009				2010				2009
Net income		$	155			$	326			$	780			$	915
Translation adjustments and other			53				20				45				202
Comprehensive income		$	208			$	346			$	825			$	1,117

     Foreign currency translation adjustments and other are primarily the result of the impact of currency exchange rates on our foreign subsidiaries.

McKESSON CORPORATION

FINANCIAL NOTES (CONCLUDED)
(UNAUDITED)

15. Segment Information

     We report our operations in two operating segments: McKesson Distribution Solutions and McKesson Technology Solutions. The factors for determining the reportable segments included the manner in which management evaluates the performance of the Company combined with the nature of the individual business activities. We evaluate the performance of our operating segments based on operating profit before interest expense, income taxes and results from discontinued operations. Financial information relating to our reportable operating segments and reconciliations to the condensed consolidated totals is as follows:

		Quarter Ended								Nine Months Ended
		December 31,								December 31,
(In millions)		2010				2009				2010				2009
Revenues
Distribution Solutions (1)
Direct distribution & services		$	19,408			$	18,992			$	57,094			$	53,880
Sales to customers’ warehouses			4,731				5,330				14,133				16,882
Total U.S. pharmaceutical distribution & services			24,139				24,322				71,227				70,762
Canada pharmaceutical distribution & services			2,574				2,421				7,485				6,816
Medical-Surgical distribution & services			744				758				2,200				2,177
Total Distribution Solutions			27,457				27,501				80,912				79,755
Technology Solutions
Services (2)			629				610				1,828				1,812
Software & software systems			135				138				408				410
Hardware			26				23				83				82
Total Technology Solutions			790				771				2,319				2,304
Total		$	28,247			$	28,272			$	83,231			$	82,059
Operating profit
Distribution Solutions (3) (4)		$	289			$	558			$	1,285			$	1,403
Technology Solutions (2)			106				81				184				300
Total			395				639				1,469				1,703
Corporate			(81	)			(105	)			(252	)			(249	)
Securities Litigation Credit			—				—				—				20
Interest Expense			(53	)			(47	)			(140	)			(142	)
Income from Continuing Operations Before Income Taxes		$	261			$	487			$	1,077			$	1,332

(1)		Revenues derived from services represent less than 1.0% of this segment’s total revenues.
(2)		Revenues and operating profit for the third quarter and first nine months of 2011 include the recognition of $23 million of previously deferred revenue for a disease management contract, for which the related expenses were previously recognized as incurred. Operating profit for the first nine months of 2011 includes a $72 million asset impairment charge for capitalized software held for sale, which was recorded in cost of sales.
(3)		Operating profit for the third quarter of 2011 includes the AWP litigation pre-tax charge of $189 million, which was recorded in operating expenses. For the first nine months of 2011 operating profit includes the AWP litigation charges of $213 million, which were recorded in operating expenses and also includes $51 million representing our share of a settlement of an antitrust class action lawsuit brought against a drug manufacturer, which was recorded as a reduction to cost of sales.
(4)		Operating profit for the third quarter and first nine months of 2010 includes a pre-tax gain of $17 million or $14 million after income taxes on the sale of our 50% equity interest in McKesson Logistics Solutions L.L.C. (“MLS”), a Canadian logistics company, which was recorded in other income, net.

McKESSON CORPORATION

FINANCIAL REVIEW
(UNAUDITED)

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

GENERAL

     Management’s discussion and analysis of financial condition and results of operations, referred to as the Financial Review, is intended to assist the reader in the understanding and assessment of significant changes and trends related to the results of operations and financial position of the Company together with its subsidiaries. This discussion and analysis should be read in conjunction with the condensed consolidated financial statements and accompanying financial notes in Item 1 of Part I of this Quarterly Report on Form 10-Q and in Item 8 of Part II of our 2010 Annual Report on Form 10-K.

     Certain statements in this report constitute forward-looking statements. See “Factors Affecting Forward-Looking Statements” included in this Quarterly Report on Form 10-Q.

Financial Overview

		Quarter Ended												Nine Months Ended
		December 31,												December 31,
(In millions, except per share amounts)		2010				2009				Change				2010				2009				Change
Revenues		$	28,247			$	28,272				—	%		$	83,231			$	82,059				1	%
Litigation Charge (Credit)			189				—			NM					213				(20	)		NM
Income from Continuing Operations Before Income Taxes		$	261			$	487				(46	)		$	1,077			$	1,332				(19	)
Income Tax Expense			(106	)			(161	)			(34	)			(369	)			(417	)			(12	)
Income from Continuing Operations			155				326				(52	)			708				915				(23	)
Discontinued Operation – gain on sale, net of tax			—				—			NM					72				—			NM
Net Income		$	155			$	326				(52	)		$	780			$	915				(15	)
Diluted Earnings Per Common Share
Continuing Operations		$	0.60			$	1.19				(50	)%		$	2.69			$	3.36				(20	)%
Discontinued Operation – gain on sale			—				—			NM					0.27				—			NM
Total		$	0.60			$	1.19				(50	)		$	2.96			$	3.36				(12	)
Weighted Average Diluted Common Shares			258				274				(6	)%			264				272				(3	)%

NM – not meaningful

     Revenues for the third quarter of 2011 remained constant at $28.2 billion and for the first nine months of 2011 increased 1% to $83.2 billion. Revenues for 2011 benefited primarily from market growth and for the third quarter of 2011 this benefit was offset by a decline in demand associated with the H1N1 flu virus.

McKESSON CORPORATION

FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)

     Income from continuing operations before income taxes for the third quarter of 2011 decreased 46% to $261 million. Results for the third quarter of 2011 were impacted by a pre-tax charge of $189 million ($133 million after-tax) for the Average Wholesale Price (“AWP”) litigation as discussed in further detail under the caption “Operating Expenses and Other Income, Net” in this financial review, a decrease in gross profit due to a decline in demand associated with the H1N1 flu virus, higher operating expenses and $34 million of acquisition costs associated with our purchase of US Oncology Holdings, Inc. (“US Oncology”). Partially offsetting these decreases was increased operating profit associated with market growth in our Distribution Solutions segment.

     Income from continuing operations before income taxes for the first nine months of 2011 decreased 19% to $1,077 million. Results for the first nine months of 2011 were impacted by pre-tax charges of $213 million ($149 million after-tax) for the AWP litigation. Income from continuing operations for the first nine months also reflect the factors affecting the third quarter of 2011, along with the following additional items incurred in our first half of 2011: a $72 million asset impairment charge for capitalized software held for sale and the benefit associated with the receipt of $51 million of cash proceeds for an antitrust settlement in our first quarter.

     Net income for the third quarter of 2011 decreased 52% to $155 million and diluted earnings per common share decreased 50% to $0.60.

     Net income for the first nine months of 2011 decreased 15% to $780 million and diluted earnings per common share decreased 12% to $2.96. Net income for the first nine months of 2011 of $780 million included a $72 million after-tax gain on the sale of our Technology Solutions segment wholly-owned subsidiary, McKesson Asia Pacific Pty Limited (“MAP”), which was sold in July 2010. Historical financial results for this subsidiary were not material.

     Diluted earnings per common share for the first nine months of 2011 of $2.96 includes $0.27 for the gain on sale of MAP. Additionally, diluted earnings per share for 2011 benefited from our repurchase of common stock.

     On December 30, 2010, we acquired all of the outstanding shares of US Oncology Holdings, Inc. of The Woodlands, Texas for approximately $2.1 billion, consisting of cash consideration of $0.2 billion and the assumption of liabilities with a fair value of $1.9 billion. As an integrated oncology company, US Oncology is affiliated with community-based oncologists, and works with patients, hospitals, payors and the medical industry across all phases of the cancer research and delivery continuum. The acquisition of US Oncology expands our existing specialty pharmaceutical distribution business and adds practice management services for oncologists. The cash paid at acquisition was funded from cash on hand. Refer to Financial Note 9, “Debt and Financing Activities,” for additional information on the assumption and funding of acquired debt. Approximately $774 million of the purchase price allocation was assigned to goodwill, which primarily reflects the expected future benefits to be realized upon integrating the business. Included in the purchase price allocation are acquired identifiable intangibles of $1.1 billion primarily representing service agreements and a trade name, the fair value of which was determined by using primarily Level 3 inputs, which are based on unobservable inputs and reflect our own assumptions. The estimated weighted average lives of the service agreements and trade name are 20 years. Financial results for US Oncology were not included in the results of operations for the third quarter and nine months ended December 31, 2010 as they were not material. These results will be included within our Distribution Solutions segment beginning in the fourth quarter of 2011. Refer to Financial Note 2, “Business Combinations,” for additional information.

McKESSON CORPORATION

FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)

Results of Operations

Revenues:

		Quarter Ended												Nine Months Ended
		December 31,												December 31,
(In millions)		2010				2009				Change				2010				2009				Change
Distribution Solutions
Direct distribution & services		$	19,408			$	18,992				2	%		$	57,094			$	53,880				6	%
Sales to customers’ warehouses			4,731				5,330				(11	)			14,133				16,882				(16	)
Total U.S. pharmaceutical distribution & services			24,139				24,322				(1	)			71,227				70,762				1
Canada pharmaceutical distribution & services			2,574				2,421				6				7,485				6,816				10
Medical-Surgical distribution & services			744				758				(2	)			2,200				2,177				1
Total Distribution Solutions			27,457				27,501				—				80,912				79,755				1
Technology Solutions
Services (1)			629				610				3				1,828				1,812				1
Software & software systems			135				138				(2	)			408				410				—
Hardware			26				23				13				83				82				1
Total Technology Solutions			790				771				2				2,319				2,304				1
Total Revenues		$	28,247			$	28,272				—			$	83,231			$	82,059				1

(1)		Revenues for the third quarter and first nine months of 2011 include recognition of $23 million of previously deferred disease management revenue.

     Total revenues remained relatively constant for the third quarter and increased 1% for the first nine months of 2011 compared to 2010. Revenues benefited primarily from market growth in our Distribution Solutions segment, which accounted for approximately 97% of our consolidated revenues. For the third quarter of 2011, this benefit was offset by a decline in demand associated with the H1N1 flu virus.

     Direct distribution and services revenues in 2011 increased primarily due to market growth, which includes price increases and increased volume from new and existing customers, partially offset by a decline in demand associated with the H1N1 flu virus. For the first nine months of 2011 these revenues also reflected a shift from sales to customers’ warehouses to direct store delivery. Sales to customers’ warehouses in 2011 decreased primarily due to reduced revenues associated with two customers and for the first nine months of 2011 were also impacted by a shift of revenues to direct store delivery. In addition, our U.S. pharmaceutical distribution revenues in 2011 were impacted by price deflation associated with brand to generic drug conversions.

     Canadian pharmaceutical distribution and services revenues increased for the third quarter and first nine months of 2011 primarily due to a change in the foreign currency exchange rate of 4% and 8%. On a constant currency basis, revenues increased 2% in the third quarter and first nine months of 2011 primarily due to market growth, which includes increased volume from existing and new customers, and a small acquisition in the second quarter of 2011. These increases were partially offset by a government-imposed price reduction for generic pharmaceuticals in certain provinces and a brand to generic conversion for one drug.

     Medical-Surgical distribution and services revenues decreased 2% for the third quarter of 2011 primarily due to a decrease in demand associated with the H1N1 flu virus, partially offset by market growth rates. Medical-Surgical distribution and services revenues increased 1% for the first nine months of 2011 primarily due to market growth rates and acquisitions, partially offset by the H1N1 flu virus decrease.

McKESSON CORPORATION

FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)

     Technology Solutions revenues increased in 2011 compared to the same periods a year ago primarily due to recognition of $23 million of previously deferred disease management revenue, partially offset by the sale of MAP in July 2010. In addition, McKesson’s Horizon Enterprise Revenue Management ^TM (“HzERM”) solution became generally available during the second quarter of 2010 and as a result we recognized previously deferred revenue.

Gross Profit:

		Quarter Ended												Nine Months Ended
		December 31,												December 31,
(Dollars in millions)		2010				2009				Change				2010				2009				Change
Gross Profit
Distribution Solutions (1)		$	1,082			$	1,104				(2	)%		$	3,239			$	3,018				7	%
Technology Solutions (2)			379				351				8				980				1,075				(9	)
Total		$	1,461			$	1,455				—			$	4,219			$	4,093				3
Gross Profit Margin
Distribution Solutions			3.94	%			4.01	%		(7		) bp			4.00	%			3.78	%		22		bp
Technology Solutions			47.97				45.53				244				42.26				46.66				(440	)
Total			5.17				5.15				2				5.07				4.99				8

(1)		Gross profit for the first nine months of 2011 includes a credit of $51 million representing our share of a settlement of an antitrust class action lawsuit brought against a drug manufacturer.
(2)		Gross profit for the third quarter and first nine months of 2011 includes recognition of $23 million of previously deferred disease management revenue and for the first nine months of 2011 includes a $72 million asset impairment charge for capitalized software held for sale.

     bp – basis points

     Gross profit remained relatively constant for the third quarter of 2011. As a percentage of revenues, gross profit increased 2 basis points (“bp”) in the third quarter of 2011. Gross profit increased 3% for the first nine months of 2011. As a percentage of revenues, gross profit increased 8 bp for the first nine months of 2011.

     Distribution Solutions segment’s gross profit margin decreased in the third quarter of 2011 primarily due to a decline in demand associated with the H1N1 flu virus, partially offset by an increase in buy side margin and increased sales of higher margin generic drugs. Distribution Solutions segment’s gross profit margin increased in the first nine months of 2011 primarily reflecting more sales of higher margin generic drugs and an increase in buy side margin, partially offset by a decline in demand associated with the H1N1 flu virus and a modest decrease in sell margin. The buy side margin primarily reflects volume and timing of compensation from branded pharmaceutical manufacturers. The first nine months of 2011 were also favorably affected by the receipt of a $51 million antitrust settlement.

     Technology Solutions segment’s gross profit margin increased in the third quarter of 2011 primarily due to recognition of $23 million of previously deferred disease management revenue, a shift to higher margin revenue and lower amortization expense for the HzERM ^TM solution compared to the prior year, partially offset by the sale of MAP and continued investment in our clinical and enterprise revenue management solutions products, which includes costs related to McKesson’s HzERM ^TM solution. Technology Solutions segment’s gross profit margin decreased in the first nine months of 2011 primarily reflecting a $72 million asset impairment charge as well as the factors affecting the third quarter. In addition, gross profit margin in 2010 was favorably impacted when HzERM ^TM became generally available late in the second quarter and, at that time we recognized previously deferred revenue for which some associated expenses were recognized as incurred in prior periods.

McKESSON CORPORATION

FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)

     Our capitalized software held for sale is amortized over three years. At each balance sheet date, or earlier if an indicator of an impairment exists, we evaluate the recoverability of unamortized capitalized software costs based on estimated future undiscounted revenues net of estimated related costs over the remaining amortization period. In October 2010, we decreased our estimated revenues over the next 24 months for our HzERM ^TM software product and as a result, concluded that the estimated future revenues, net of estimated related costs, were insufficient to recover its carrying value. Accordingly, we recorded a $72 million non-cash impairment charge at September 30, 2010 within our Technology Solutions segment’s cost of sales to reduce the carrying value of the software product to its net realizable value.

Operating Expenses and Other Income, Net:

		Quarter Ended												Nine Months Ended
		December 31,												December 31,
(Dollars in millions)		2010				2009				Change				2010				2009				Change
Operating Expenses
Distribution Solutions (1)		$	797			$	568				40	%		$	1,963			$	1,645				19	%
Technology Solutions			273				271				1				798				778				3
Corporate			84				107				21				260				255				2
Securities litigation credit			—				—			NM					—				(20	)		NM
Total		$	1,154			$	946				22			$	3,021			$	2,658				14
Operating Expenses as a Percentage of Revenues
Distribution Solutions			2.90	%			2.07	%		83		bp			2.43	%			2.06	%		37		bp
Technology Solutions			34.56				35.15				(59	)			34.41				33.77				64
Total			4.09				3.35				74				3.63				3.24				39
Other Income, Net
Distribution Solutions (2)		$	4			$	22				(82	)%		$	9			$	30				(70	)%
Technology Solutions			—				1				(100	)			2				3				(33	)
Corporate			3				2				50				8				6				33
Total		$	7			$	25				(72	)		$	19			$	39				(51	)

(1)		Operating expenses for the third quarter and first nine months of 2011 include $189 million and $213 million for AWP litigation charges and $24 million of expenses related to the acquisition of US Oncology.
(2)		Includes the sale of our 50% equity interest in MLS in the third quarter of 2010.

     Operating expenses increased 22% and 14% for the third quarter and the first nine months of 2011 compared to the same periods a year ago. As a percentage of revenues, operating expenses increased 74 bp and 39 bp for the same periods a year ago. The increase for the third quarter was primarily due to the AWP litigation charge, higher costs associated with employee compensation and benefits, including the McKesson Corporation Profit Sharing Investment Plan (“PSIP”) expenses, and due to expenses associated with the acquisition of US Oncology. For the first nine months of 2011, operating expenses also increased primarily due to a $24 million charge for our AWP litigation and foreign currency fluctuations. In addition, operating expenses for the first nine months of 2010 benefited from a $20 million credit relating to our securities litigation.

McKESSON CORPORATION

FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)

     Following our most recent review of the reserve for estimated probable losses from current and possible future public entity AWP claims, which review included consideration of the pace and progress of settlement discussions during and after the third quarter relating to state and federal Medicaid claims, we recorded a pre-tax charge of $189 million within our Distribution Solutions segment’s operating expenses during the third quarter of 2011. The results of our Distribution Solution segment for the first nine months of 2011 also reflect a pre-tax charge of $24 million for the settlement with the State of Connecticut relating to AWP claims. The settlement included an express denial of liability and a release by Connecticut of the Company as to all matters alleged or which could have been alleged in the action. A cash payment of $26 million was made in the third quarter of 2011 for this settlement. As of December 31, 2010, the reserve relating to AWP public entity claims was $330 million and was included in other current liabilities in our condensed consolidated balance sheet. Additional information regarding our AWP litigation is included in Financial Note 13, “Other Commitments and Contingent Liabilities,” to the accompanying condensed consolidated financial statements.

     As previously reported in our 2010 Annual Report, the PSIP was a member of the settlement class in the Consolidated Securities Litigation Action. On October 9, 2009, the PSIP received approximately $119 million of the Consolidated Securities Litigation Action proceeds. Approximately $42 million of the proceeds were attributable to the allocated shares of McKesson common stock owned by the PSIP participants during the Consolidated Securities Litigation Action class-holding period and were allocated to the respective participants on that basis in the third quarter of 2010. Approximately $77 million of the proceeds were attributable to the unallocated shares (the “Unallocated Proceeds”) of McKesson common stock owned by the PSIP in an employee stock ownership plan (“ESOP”) suspense account. In accordance with the plan terms, the PSIP distributed all of the Unallocated Proceeds to current PSIP participants after the close of the plan year in April 2010. The receipt of the Unallocated Proceeds by the PSIP was reimbursement for the loss in value of the Company’s common stock held by the PSIP in its ESOP suspense account during the Consolidated Securities Litigation Action class holding period and was not a contribution made by the Company to the PSIP or ESOP. Accordingly, there were no accounting consequences to the Company’s financial statements relating to the receipt of the Unallocated Proceeds by the PSIP.

     As a result of the PSIP’s receipt of the $119 million settlement, in 2010 the Company contributed $1 million to the PSIP. Accordingly, PSIP expense for 2010 was nominal. In 2011, the Company resumed its contributions to the PSIP, and the expense for 2011 is expected to be approximately $60 million.

     PSIP expense by segment for the quarters and nine months ended December 31, 2010 and 2009 was as follows:

		Quarter Ended								Nine Months Ended
		December 31								December 31,
(In millions)		2010				2009				2010				2009
Distribution Solutions		$	5			$	—			$	17			$	—
Technology Solutions			7				—				24				1
Corporate			1				—				3				—
PSIP Expense		$	13			$	—			$	44			$	1
Cost of sales (1)		$	3			$	—			$	10			$	—
Operating expenses			10				—				34				1
PSIP expense		$	13			$	—			$	44			$	1

(1)		Amounts recorded to cost of sales pertain solely to our Technology Solutions segment.

     Distribution Solutions segment’s operating expenses and operating expenses as a percentage of revenues increased for the third quarter and the first nine months of 2011 compared to the same periods a year ago primarily reflecting higher employee compensation and benefit costs, foreign currency fluctuations, the AWP litigation charge and $24 million of expenses associated with the acquisition of US Oncology.

     Technology Solutions segment’s operating expenses increased for the third quarter and the first nine months of 2011 compared to the same periods a year ago primarily reflecting our continued investment in research and development activities and higher employee compensation and benefit costs. These increases were partially offset by cost controls, reduced expenses from MAP, which was sold in July 2010, and a release of accounts receivable reserves in the first quarter of 2011.

McKESSON CORPORATION

FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)

     Corporate expenses decreased for the third quarter of 2011 primarily due to a decline in legal fees compared to the third quarter of 2010, partially offset by higher employee compensation and benefits costs. Corporate expenses for the first nine months of 2011 increased primarily due to an asset impairment charge for certain tangible property, higher compensation and benefits costs, partially offset by lower fees associated with our accounts receivable facility. As a result of our adoption of a new accounting standard for transfers of financial assets on April 1, 2010, fees associated with our accounts receivable securitization facility are now recorded in interest expense. Prior to 2011 these fees were recorded in Corporate administrative expenses. See Financial Note 9, “Debt and Financing Activities,” for further information.

     Other income, net for 2011 decreased compared to 2010, which included a $17 million pre-tax gain on the sale of our 50% equity interest in MLS.

Segment Operating Profit and Corporate Expenses, Net:

		Quarter Ended												Nine Months Ended
		December 31,												December 31,
(Dollars in millions)		2010				2009				Change				2010				2009				Change
Segment Operating Profit (1)
Distribution Solutions (2) (3)		$	289			$	558				(48	)%		$	1,285			$	1,403				(8	)%
Technology Solutions (4)			106				81				31				184				300				(39	)
Subtotal			395				639				(38	)			1,469				1,703				(14	)
Corporate Expenses, Net			(81	)			(105	)			(23	)			(252	)			(249	)			1
Securities Litigation Credit			—				—			NM					—				20			NM
Interest Expense			(53	)			(47	)			13				(140	)			(142	)			(1	)
Income from Continuing Operations Before Income Taxes		$	261			$	487				(46	)		$	1,077			$	1,332				(19	)
Segment Operating Profit Margin
Distribution Solutions			1.05	%			2.03	%		(98		) bp			1.59	%			1.76	%		(17		) bp
Technology Solutions			13.42				10.51				291				7.93				13.02				(509	)

(1)		Segment operating profit includes gross profit, net of operating expenses, plus other income for our two operating segments.
(2)		Operating profit for the third quarter and first nine months includes $189 million and $213 million for AWP litigation charges and $24 million of expenses related to the acquisition of US Oncology. Operating profit for the first nine months of 2011 also includes $51 million representing our share of a settlement of an anti-trust class action lawsuit brought against a drug manufacturer.
(3)		Other income, net for the third quarter of 2010 includes the MLS gain on sale of $17 million.
(4)		Operating profit for the third quarter and first nine months of 2011 includes recognition of $23 million of previously deferred disease management revenue and for the first nine months of 2011 operating profit includes a $72 million asset impairment charge for capitalized software held for sale.

     Operating profit margin for our Distribution Solutions segment decreased in the third quarter of 2011 primarily due to the AWP litigation charge, a lower gross profit margin, which includes a decline in demand associated with the H1N1 flu virus, and higher operating expenses as a percentage of revenues. Operating profit margin for our Distributions Solutions segment decreased in the first nine months of 2011 primarily due to AWP litigation charges and higher operating expenses as a percentage of revenue, partially offset by a higher gross profit margin, which includes a $51 million antitrust settlement.

     Operating profit margin for our Technology Solutions segment increased in the third quarter of 2011 primarily reflecting an increase in gross profit margin, which includes recognition of $23 million of previously deferred disease management revenue, and a decrease in operating expenses as a percentage of revenues. Operating profit margin decreased in the first nine months of 2011 primarily reflecting a decrease in gross profit margin, which includes the $72 million asset impairment charge and recognition of $23 million of previously deferred disease management revenue, and an increase in operating expenses as a percentage of revenues.

McKESSON CORPORATION

FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)

     Corporate expenses, net of other income decreased for the third quarter of 2011 and increased for the first nine months of 2011 primarily reflecting changes in operating expenses.

     Litigation credit: In the second quarter of 2010, we recorded a net credit of $20 million relating to settlements from the securities litigation.

     Interest Expense: Interest expense increased in the third quarter of 2011 primarily due to bridge loan fees related to the acquisition of US Oncology and fees from our accounts receivable securitization facility which are recorded in interest expense commencing in 2011, partially offset by the repayment of $215 million of our long-term debt in March 2010.

     Income Taxes: The Company’s reported income tax rates for the third quarters of 2011 and 2010 were 40.6% and 33.1% and for the first nine months of 2011 and 2010 were 34.3% and 31.3%. Fluctuations in our reported income tax rates are primarily due to changes within state and foreign tax rates resulting from our business mix, including varying proportions of income attributable to foreign countries that have lower income tax rates. The 2011 income tax rates include a tax benefit for the reinstatement of the federal research and development tax credit which was signed into law in December 2010. In addition, during the third quarter and first nine months of 2011, income tax expense included net discrete items of $18 million and $12 million of expense.

     Discontinued Operation: In July 2010, our Technology Solutions segment sold its wholly-owned subsidiary, McKesson Asia Pacific Pty Limited (“MAP”), a provider of phone and web-based healthcare services in Australia and New Zealand, for net sales proceeds of $109 million. The divestiture generated a pre-tax and after-tax gain of $95 million and $72 million. As a result of the sale we were able to utilize capital loss carry-forwards for which we previously recorded a valuation allowance of $15 million. The release of the valuation allowance is included as a tax benefit in our after-tax gain on the divestiture. The after-tax gain on disposition was recorded as a discontinued operation in our condensed statement of operations in the second quarter of 2011. Should we incur a capital gain within our continuing operations during the remainder of 2011, some portion or all of the $15 million valuation allowance reversal could be reclassified to continuing operations. The historical financial operating results and net assets of MAP were not material to our condensed consolidated financial statements for all periods presented.

     Net Income: Net income was $155 million and $326 million for the third quarters of 2011 and 2010, or $0.60 and $1.19 per diluted common share. Net income was $780 million and $915 million for the first nine months of 2011 and 2010, or $2.96 and $3.36 per diluted common share. Net income and diluted earnings per common share for the third quarter included a pre-tax charge of $189 million ($133 million after-tax) and for the first nine months of 2011 $213 million ($149 million after-tax) for the AWP litigation as discussed in further detail under the caption “Operating Expenses and Other Income, net” in this financial review. Net income and diluted earnings per common share for the first nine months of 2011 also included a gain of $72 million or $0.27 per diluted share relating to our sale of MAP.

     Weighted Average Diluted Common Shares Outstanding (“WASO”): Diluted earnings per common share were calculated based on a weighted average number of shares outstanding of 258 million and 274 million for the third quarters of 2011 and 2010 and 264 million and 272 million for the nine months ended December 31, 2010 and 2009. Our WASO decreased primarily reflecting a decrease in the number of common shares outstanding as a result of stock repurchases, partially offset by the exercise of share-based awards and an increase in common stock equivalents, primarily reflecting our higher stock price.

New Accounting Developments

     New accounting pronouncements that we have recently adopted as well as those that have been recently issued but not yet adopted by us are included in Financial Note 1, “Significant Accounting Policies,” to the accompanying condensed consolidated financial statements appearing in this Quarterly Report on Form 10-Q.

McKESSON CORPORATION

FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)

Financial Condition, Liquidity and Capital Resources

     We expect our available cash generated from operations, together with our existing sources of liquidity from our accounts receivable securitization facility and short-term borrowings under the Bridge Loan facility, revolving credit facility and commercial paper, will be sufficient to fund our long-term and short-term capital expenditures, working capital and other cash requirements. In addition, from time-to-time, we may access the long-term debt capital markets to discharge our other liabilities.

     Operating activities provided cash of $1.3 billion and $1.7 billion during the first nine months of 2011 and 2010. Operating activities for 2011 benefited from operations and management of working capital. Cash flows from operations can be significantly impacted by factors such as the timing of receipts from customers, inventory receipts and payments to vendors. Operating activities for 2011 include non-cash charges of $213 million for the AWP litigation and $72 million for an asset impairment of software held for sale. Operating activities for 2010 include private payor settlement payments of $350 million related to our AWP litigation.

     Investing activities utilized cash of $0.5 billion and $0.2 billion during the first nine months of 2011 and 2010. Investing activities for 2011 includes $0.2 billion of cash paid for our acquisition of US Oncology, net of cash acquired, and $0.1 billion of cash received from the sale of MAP.

     Financing activities utilized cash of $1.4 billion and $0.2 billion during the first nine months of 2011 and 2010. Financing activities for 2011 and 2010 include $1.5 billion and $0.3 billion in cash paid for stock repurchases. In December of 2010 we assumed $1.9 billion of debt in connection with the acquisition of US Oncology, which was a non-cash transaction.

     In April 2008, the Company’s Board of Directors (the “Board”) approved a plan to repurchase $1.0 billion of the Company’s common stock, of which $531 million remained available as of March 31, 2010.

     In April 2010, the Board authorized a plan to repurchase up to an additional $1.0 billion of the Company’s common stock. In May 2010, we entered into a capped accelerated share repurchase (“ASR”) program with a third party financial institution to repurchase $1.0 billion of the Company’s common stock. As a result of the ASR program, we repurchased 12.7 million shares for $1.0 billion during the first quarter of 2011, which was funded with cash on hand. The ASR program was completed on July 26, 2010 and we received 1.9 million additional shares on July 29, 2010. The total number of shares repurchased under the ASR program was 14.6 million shares at an average price per share of $68.66.

     In addition, we repurchased 8.6 million shares for $531 million during the second quarter of 2011.

     As a result of these purchases, the April 2008 and April 2010 plans have been completed and no amounts remain authorized for repurchase under these plans.

     In October 2010, the Board authorized a plan to repurchase up to an additional $1.0 billion of the Company’s common stock. No shares were repurchased during the third quarter of 2011.

     In May 2010, the quarterly dividend was raised from $0.12 to $0.18 per common share. The Company anticipates that it will continue to pay quarterly cash dividends in the future. However, the payment and amount of future dividends remain within the discretion of the Board and will depend upon the Company’s future earnings, financial condition, capital requirements and other factors.

     We believe that our operating cash flow, financial assets and current access to capital and credit markets, including our existing credit facilities, will give us the ability to meet our financing needs for the foreseeable future. However, there can be no assurance that continued or increased volatility and disruption in the global capital and credit markets will not impair our liquidity or increase our costs of borrowing.

McKESSON CORPORATION

FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)

     Selected Measures of Liquidity and Capital Resources

		December 31,				March 31,
(Dollars in millions)		2010				2010
Cash and cash equivalents		$	3,213			$	3,731
Working capital			2,008				4,492
Debt, net of cash and cash equivalents			849				(1,434	)
Debt to capital ratio (1)			36.5	%			23.4	%
Net debt to net capital employed (2)			10.7				(23.5	)
Return on stockholders’ equity (3)			15.9				18.7

     Working capital primarily includes cash and cash equivalents, receivables and inventories, net of drafts and accounts payable, deferred revenue and other current liabilities. Our Distribution Solutions segment requires a substantial investment in working capital that is susceptible to large variations during the year as a result of inventory purchase patterns and seasonal demands. Inventory purchase activity is a function of sales activity and customer requirements. Consolidated working capital decreased primarily due to an increase in the current portion of long-term debt and a decrease in cash and cash equivalents associated with the acquisition of US Oncology. See Financial Note 2, “Business Combinations,” for further information.

     Our ratio of net debt to net capital employed increased in 2011 primarily due to an increase in total debt as a result of the US Oncology acquisition. Cash equivalents are invested in overnight repurchase agreements collateralized by US Treasury and/or securities that are guaranteed or sponsored by the US government, a US government money market fund, a AAA rated prime money market fund denominated in US dollars, a AAA rated prime money market fund denominated in British pound sterling, and Canadian government securities.

     A majority of the remaining cash and cash equivalents is deposited with several financial institutions. Bank deposits in the United States may exceed the amount insured by the Federal Deposit Insurance Corporation. We mitigate the risk of our short-term investment portfolio by investing in government securities, monitoring risk profiles and investment strategies of money market funds and depositing funds with reputable financial institutions.

     Contractual Obligations

     Upon our purchase of US Oncology in December 2010, we assumed the outstanding debt of US Oncology Holdings, Inc. and its wholly owned subsidiary US Oncology, Inc. Immediately prior to our acquisition, US Oncology Holdings, Inc. called for redemption all of its outstanding Senior Unsecured Floating Rate Toggle Notes (“Floating Rate Notes”) due 2012, and US Oncology, Inc. called for redemption all of its outstanding 9.125% Senior Secured Notes due 2017 (“Secured Notes”) and 10.75% Senior Subordinated Notes due 2014 (“Subordinated Notes”). Redemption will occur during our fourth quarter and as a result all of these notes are included in the current portion of long-term debt in our condensed consolidated balance sheet. The fair value of the outstanding debt, including principal amounts, and associated redemption premiums is $1.8 billion.

     We redeemed the Floating Rate Notes, including accrued interest, on January 31, 2011 for $540 million. In the fourth quarter of 2011, we will redeem the Secured Notes and the Subordinated Notes using cash on hand and borrowings under our Senior Bridge Term Loan Facility.

McKESSON CORPORATION

FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)

     In connection with our purchase of US Oncology, we assumed non-cancelable operating lease obligations of office space, certain comprehensive cancer centers and certain equipment. These acquired lease obligations are additive to the operating lease obligations disclosed in our obligations and commitments table in our 2010 Annual Report. As of December 31, 2010, total future minimum lease payments, including escalation provisions, of the acquired leases are approximately $535 million. Minimum lease payments due under these acquired leases are as follows: $20 million for the remainder of 2011, $79 million, $69 million, $61 million, and $53 million for 2012 through 2015 and $253 million thereafter.

     Credit Resources

     We fund our working capital requirements primarily with cash and cash equivalents, our accounts receivable securitization facility, and short-term borrowings under the revolving credit facility and commercial paper.

     Senior Bridge Term Loan Facility

     In connection with our execution of an agreement to acquire US Oncology, in November 2010 we entered into a $2.0 billion unsecured Senior Bridge Term Loan Agreement (“Bridge Loan”). In December 2010, we reduced the Bridge Loan commitment to $1.0 billion. On January 31, 2011, we borrowed $1 billion under the Bridge Loan. Borrowings under the Bridge Loan must be repaid in full no later than December 30, 2011 or, in full or in part, upon certain events occurring prior to such time, including specified debt and equity issuances and asset sales. The Bridge Loan bears interest based on the London Interbank Offered Rate plus a margin based on the Company’s credit ratings and the amount of time any borrowings under the Bridge Loan remain outstanding. Amounts repaid under the Bridge Loan cannot be redrawn by the Company. The Bridge Loan contains debt covenants similar to those in our existing revolving credit facility. We anticipate repaying funds obtained from the Bridge Loan and replacing cash resources used to redeem the US Oncology debt with long-term financing.

     Accounts Receivable Securitization Facility

     In May 2010, we renewed our accounts receivable securitization facility (the “Facility”) for an additional one year period under terms substantially similar to those previously in place, and in doing so we increased our committed balance from $1.1 billion to $1.35 billion. From time-to-time, the available amount of the Facility may be less than $1.35 billion based on accounts receivable concentration limits and other eligibility requirements. The renewed Facility will expire in May 2011.

     Through the Facility, McKesson Corporation, the parent company, transfers certain U.S. pharmaceutical trade accounts receivable on a non-recourse basis to a wholly-owned and consolidated subsidiary which then sells these receivables to a special purpose entity (“SPE”), which is a wholly-owned, bankruptcy-remote subsidiary of McKesson Corporation that is consolidated in our financial statements. This SPE then sells undivided interests in the pool of accounts receivable to third-party purchaser groups (the “Purchaser Groups”), which includes financial institutions and commercial paper conduits.

     Prior to 2011, transactions in the Facility were accounted for as sales because we met the requirements of the existing accounting guidance and accounts receivable sold would have been excluded from accounts receivable, net in the accompanying condensed consolidated balance sheet. On April 1, 2010, the Company adopted the new accounting standard for transfers of financial assets. Transactions under the Facility no longer meet the requirements for sales treatment and consequently, the related accounts receivable would continue to be recognized on the Company’s condensed consolidated balance sheet. Proceeds received from the Purchaser Groups would be shown as secured borrowings.

     At December 31, 2010, there were no securitized accounts receivable balances or secured borrowings outstanding under the Facility. As of March 31, 2010, there were no accounts receivable sold under the Facility. Additionally, there were no sales of interests to the Purchaser Groups in the quarter and nine months ended December 31, 2010 or 2009.

McKESSON CORPORATION

FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)

     Additional information regarding our accounts receivable securitization facility is included in Financial Note 9, “Debt and Financing Activities,” to the accompanying condensed consolidated financial statements appearing in this Quarterly Report on Form 10-Q.

     Revolving Credit Facility